Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amcor Plc

Franklin Resources

V.F.

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. By yield, VFC topped all Aristocrats. Top-ten yields from TROW, ESS, FRT, AMCR, ABBV, O, IBM, MMM, WBA, & VFC, averaged 4.38%.

4 Dividend Aristocrat Buys For February

CVS Health

Oak Street Health

CVS Health's plan to buy Oak Street Health for $10.6 billion adds a large network of doctor-staffed clinics primarily used by seniors amid a doctor buyout wave by retailers including Walgreens, Walmart and Amazon.

CVS Health Bids $10.6 Billion For Oak Street Health, Countering Walgreens Doctor Clinic Push

Lovesac Company

Teva Pharmaceutical

These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite.

Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026

Essex Property Trust

For investors looking for reliable dividend growth stocks through all sorts of economic environments, the Dividend Aristocrats are a great place to look. That is because Dividend Aristocrats have grown their dividends for at least 25 years in a row, including through the economic recessions and other black swan events (such as the Covid-19 outbreak) that have taken place over that period.

3 Top Dividend Aristocrats for 2023

Coterra Energy

EPR Properties

FS KKR Capital Corp

Altria

Verizon

Just when the risk-on crowd was warmed up and ready to party, and everybody was cheering what many thought was dovish commentary from Federal Reserve Chair Jay Powell, the January job report dropped a bomb when it was announced Friday a stunning 517,000 jobs were added, versus expectations for 180,000.

Time to Sell the Bear Market Rally and Move to 7 ‘Strong Buy' Big-Dividend Winners

Apple

Amgen

Boeing

Salesforce

Cisco Systems

Chevron

Disney

Dow Inc

Intel

JPMorgan Chase & Co

Coca-Cola

Microsoft

UnitedHealth Group

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.” – Dow Jones & Co. The highest-yield 10 are February's Dogs of the Dow: KO, CSCO, AMGN, CVX, DOW, IBM, INTC, MMM, WBA, and VZ, averaging a 4.41% annual yield.

Buy 3 February Dogs Of The Dow, Watch 2 More

Enterprise Products Partners

These highly profitable, industry-leading businesses can deliver triple-digit total returns for retired investors.

Retirees Can Double Their Money in 5 Years With These 3 Time-Tested Stocks

Select analysts expect these profitable and time-tested Dow components to soar in the new year.

3 Dow Jones Industrial Average Stocks With 45% to 82% Upside in 2023, According to Wall Street

Lululemon Athletica

TROY, Mich. , Jan. 30, 2023 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Lululemon Athletica Inc. (NASDAQ: LULU) as its "Stock to Study" and Walgreens Boots Alliance Inc. (NASDAQ: WBA) as its "Undervalued Stock" in the April 2023 issue for investors' informational and educational use.

BetterInvesting™ Magazine Update on Lululemon Athletica Inc. and Walgreens Boots Alliance, Inc.

Would now be a good time to add these Dow Jones stocks to your radar?

3 Dow Jones Stocks To Watch Ahead Of February 2023

AbbVie

Abbott Labs

Automatic Data Processing

Aflac

Cigna

Colgate-Palmolive

Clorox

Emerson Electric

Illinois Tool Works

Johnson & Johnson

Lockheed Martin

Medtronic

QUALCOMM

Rio Tinto plc Sponsored

AT&T

Waste Management

Walmart

We present the 2022 year-end review of our eight-year-old Passive DGI-Core Portfolio. We consider this portfolio and strategy as the foundation of our overall portfolio. We will provide updates on changes, additional investments, dividends collected, and an overall 2022 performance.

The 4% DGI Core Portfolio: 2022 Year-End Review

Ecolab

W.W. Grainger

Lowe's

McCormick

Realty Income Corp

PPG Industries

Sherwin-Williams

Stanley Black & Decker

Sysco

T. Rowe Price Group

West Pharmaceutical Services

NOBL fell 4.12% in December, which brings the Fund's return for the year to a loss of 6.5%. Thus far this month, through January 25th, the dividend aristocrat ETF is up 1.92% and starting the year on a bright note.

My Best Dividend Aristocrats For February 2023

C.H. Robinson Worldwide

TrueShares Low Volatility Equity Income ETF

Nordson

ProShares S&P 500 Dividend Aristocrats ETF

J. M. Smucker

It's tough to beat the "Dividend Aristocrats" for bankable dividend stocks. And investors now have three more in the S&P 500 to choose from.

There's 3 New Standout Dividend Stocks — And 3 Pay The Most

Ares Capital

New York Community Bancorp

Owl Rock Capital Corp

Virtus InfraCap U.S. Preferred Stock ETF

abrdn World Healthcare Fund 

The Dividend Harvesting Portfolio is now generating $766.99 in annual dividends, yielding 7.65%. The Dividend Harvesting portfolio has a 73.74% record of finishing the week in the black since its inception, 73/99 weeks.

Dividend Harvesting Portfolio Week 99 Update: $9,900 Allocated, $766.99 In Projected Dividends

Here's how these two retail-pharmacy leaders stack up against each other.

Better Stock to Buy in 2023: CVS Health or Walgreens Boots Alliance?

News for Walgreens Stock (WBA)